BR0314617A - Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados - Google Patents

Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados

Info

Publication number
BR0314617A
BR0314617A BR0314617-0A BR0314617A BR0314617A BR 0314617 A BR0314617 A BR 0314617A BR 0314617 A BR0314617 A BR 0314617A BR 0314617 A BR0314617 A BR 0314617A
Authority
BR
Brazil
Prior art keywords
cardioprotection
neuroprotection
intravenous administration
ischemic event
halogenated volatile
Prior art date
Application number
BR0314617-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Raul Trillo
Ralph Lessor
Satish Pejaver
Navneet Puri
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of BR0314617A publication Critical patent/BR0314617A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314617-0A 2002-10-11 2003-10-09 Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados BR0314617A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11
PCT/US2003/031826 WO2004032858A2 (en) 2002-10-11 2003-10-09 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics

Publications (1)

Publication Number Publication Date
BR0314617A true BR0314617A (pt) 2005-08-02

Family

ID=32094122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314617-0A BR0314617A (pt) 2002-10-11 2003-10-09 Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados

Country Status (19)

Country Link
US (1) US7999011B2 (enExample)
EP (1) EP1558226B1 (enExample)
JP (1) JP5210486B2 (enExample)
KR (2) KR20120030598A (enExample)
CN (2) CN1703209A (enExample)
AT (1) ATE546136T1 (enExample)
AU (1) AU2003282464B2 (enExample)
BR (1) BR0314617A (enExample)
CA (1) CA2500310C (enExample)
DK (1) DK1558226T3 (enExample)
ES (1) ES2382911T3 (enExample)
HK (1) HK1079703A1 (enExample)
IL (1) IL167472A (enExample)
MX (1) MXPA05003741A (enExample)
NZ (1) NZ539298A (enExample)
PL (1) PL219493B1 (enExample)
RU (1) RU2350323C2 (enExample)
WO (1) WO2004032858A2 (enExample)
ZA (1) ZA200502741B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
WO2008036858A2 (en) * 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
WO2009059989A1 (de) * 2007-11-06 2009-05-14 B. Braun Melsungen Ag Einen hydrophoben wirkstoff enthaltende wässrige emulsionen
WO2009094459A1 (en) * 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CN102006903A (zh) * 2008-01-22 2011-04-06 维波真尼克斯公司 挥发性麻醉组合物和应用方法
CA3031836A1 (en) 2009-05-05 2010-11-11 Board Of Regents, The University Of Texas System Formulations of volatile anesthetics for reducing inflammation
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
RU2408396C1 (ru) * 2009-07-30 2011-01-10 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и федеральному развитию" Комбинированная двухсегментарная регионарная анестезия при выполнении каротидной эндартерэктомии у больных критической ишемией нижних конечностей и выраженным болевым синдромом
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
CN107260670A (zh) * 2011-06-24 2017-10-20 维普詹尼克斯公司 用于治疗皮肤病症或疾病的新型制剂和方法
JP6669645B2 (ja) * 2013-03-15 2020-03-18 ベイポジェニックス インコーポレイテッド 新規な鎮痛組成物
ITMO20130075A1 (it) * 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
WO1995008544A1 (en) * 1993-09-24 1995-03-30 The University Of British Columbia Aminocyclohexylesters and uses thereof
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
CA2416535C (en) 2000-07-26 2010-11-16 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
KR101403264B1 (ko) 2014-06-02
WO2004032858A2 (en) 2004-04-22
WO2004032858A3 (en) 2004-09-23
HK1079703A1 (zh) 2006-04-13
CN102283821A (zh) 2011-12-21
MXPA05003741A (es) 2005-06-17
ZA200502741B (en) 2006-02-22
US20040127578A1 (en) 2004-07-01
EP1558226A2 (en) 2005-08-03
AU2003282464A1 (en) 2004-05-04
US7999011B2 (en) 2011-08-16
NZ539298A (en) 2008-11-28
PL376217A1 (en) 2005-12-27
IL167472A (en) 2013-10-31
AU2003282464B2 (en) 2010-02-25
KR20050056230A (ko) 2005-06-14
KR20120030598A (ko) 2012-03-28
DK1558226T3 (da) 2012-05-07
JP5210486B2 (ja) 2013-06-12
PL219493B1 (pl) 2015-05-29
ATE546136T1 (de) 2012-03-15
ES2382911T3 (es) 2012-06-14
CN1703209A (zh) 2005-11-30
JP2006504740A (ja) 2006-02-09
EP1558226B1 (en) 2012-02-22
RU2005114008A (ru) 2005-10-27
CA2500310A1 (en) 2004-04-22
EP1558226A4 (en) 2008-04-02
RU2350323C2 (ru) 2009-03-27
CA2500310C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
RUBIN Intracordal injection of silicone in selected dysphonias
BR0314617A (pt) Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados
Compere et al. Major complications after 400 continuous popliteal sciatic nerve blocks for post‐operative analgesia
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
JP2006501240A5 (enExample)
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
KR100535554B1 (ko) 소아과 수술에서의 레보부피바카인의 용도
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
Younis et al. Taking the'ouch'out-effect of buffering commercial xylocaine on infiltration and procedure pain-a prospective, randomised, double-blind, controlled trial
Jayakaran et al. Local anesthetics in pediatric dental practice
Gupta et al. “Sodium bicarbonate”: an adjunct to painless palatal anesthesia
Alioto et al. Hematoma block for ankle fractures: a safe and efficacious technique for manipulations
Kulkarni et al. Painless anaesthesia in pediatric dentistry: an updated review
Jadon et al. Serratus anterior plane block for pain relief in multiple fractured ribs (MFRs); injection of local anesthetic above the serratus or below the serratus anterior muscle-a case report. Anesth Med Pract J 2016: G103. DOI: 10.29011
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
Barker et al. Femoral nerve blockade administered preclinically for pain relief in severe knee trauma is more feasible and effective than intravenous metamizole: a randomized controlled trial
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Rao et al. Efficacy of local anesthetic wound infiltration in temporomandibular joint ankylosis surgery for control of postoperative pain: A Prospective, Randomized Controlled, and Double-Blinded Trial
UA27230C2 (uk) Похідні андростану, заміщені по 16-му положенню четвертинною амонієвою групою, для використання як нервово-м'язових блокаторів та фармацевтична композиція, що здатна викликати нервово-м'язову блокаду
Padmanabhan et al. Dental Anesthesia: Can Needle-Free Injections Help
Upadya et al. Anesthesia for dermatological surgery
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
Arangannal et al. Intranasal Local Anaesthesia: A Recent Advancement in Pediatric Dentistry.
Gupta et al. Intrathecal Administration of Bupivacaine and Bupivacaine With Different Doses of Clonidine For Post-operative Analgesia in Lower Abdominal and Lower Limb Surgeries–A Comparative Study

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/02, A61K 9/107, A61K 47/24, A61K 47/44, A61K 31/02, A61P 25/00, A61P 25/08, A61P 9/10, A61P 43/00

Ipc: A61K 31/02 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]